From April 2020 to April 2022, patients with PTMC who underwent MWA treatment were collected retrospectively. Ultrasound (US) or contrast-enhanced ultrasound (CEUS) was performed at 1 day, 1, 3, 6, 12, 18 and 24 months after MWA to observe the curative effect after ablation. The volume, volume reduction rate (VRR) and complete disappearance rate of the ablation zone at each time point were calculated. Univariate and multivariate logistic regression analysis were used to determine the prognostic factors associated with the disappearance of the ablation zone after MWA, and the nomogram was established and validated.
72 patients with PTMCs underwent MWA were enrolled into this study. After MWA, no tumor progression (residual, recurrence or lymph node metastasis) and major postoperative complications occurred. The ablation zone in 28 (38.89%) patients did not completely disappear after MWA in the follow-up period. Three variables, including age (odds ratio [OR]: 1.216), calcification type (OR: 12.283), initial maximum diameter (OR: 2.051) were found to be independent prognostic factors predicting ablation zone status after MWA by multivariate analysis. The above variables and outcomes were visualized by nomogram (C-index=0.847).
MWA was a safe and effective treatment for PTMC. Older patients with macrocalcification and larger size PTMCs were more unlikely to obtain complete disappearance of ablation zones. Incomplete disappearance of ablation zone was not related to recurrence.
■从2020年4月至2022年4月,回顾性收集接受MWA治疗的PTMC患者。在第1天进行超声(US)或对比增强超声(CEUS),MWA消融后1、3、6、12、18、24个月不雅察疗效。音量,计算每个时间点消融区的体积减少率(VRR)和完全消失率.单因素和多因素logistic回归分析用于确定MWA后消融区消失的预后因素,并建立和验证了列线图。
■72例接受MWA的PTMC患者被纳入本研究。在MWA之后,无肿瘤进展(残留,复发或淋巴结转移)和发生主要术后并发症。28例(38.89%)患者在随访期间经MWA后消融区未完全消失。三个变量,包括年龄(赔率比[OR]:1.216),钙化类型(OR:12.283),多变量分析发现初始最大直径(OR:2.051)是预测MWA后消融区状态的独立预后因素.上述变量和结果通过列线图(C指数=0.847)可视化。
■MWA是一种安全有效的PTMC治疗方法。具有大钙化和较大大小PTMC的老年患者更不可能获得消融区的完全消失。消融区不完全消失与复发无关。